Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial

ABSTRACT: The MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-β1b) investigates the efficacy of a combination therapy of lopinavir/ritonavir and recombinant interferon-β1b provided with standard supportive care, compared to placebo provided with sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Arabi, Yaseen M., Asiri, Ayed Y., Assiri, Abdullah M., Aziz Jokhdar, Hani A., Alothman, Adel, Balkhy, Hanan H., AlJohani, Sameera, Al Harbi, Shmeylan, Kojan, Suleiman, Al Jeraisy, Majed, Deeb, Ahmad M., Memish, Ziad A., Ghazal, Sameeh, Al Faraj, Sarah, Al-Hameed, Fahad, AlSaedi, Asim, Mandourah, Yasser, Al Mekhlafi, Ghaleb A., Sherbeeni, Nisreen Murad, Elzein, Fatehi Elnour, Almotairi, Abdullah, Al Bshabshe, Ali, Kharaba, Ayman, Jose, Jesna, Al Harthy, Abdulrahman, Al Sulaiman, Mohammed, Mady, Ahmed, Fowler, Robert A., Hayden, Frederick G., Al-Dawood, Abdulaziz, Abdelzaher, Mohamed, Bajhmom, Wail, Hussein, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942374/
https://www.ncbi.nlm.nih.gov/pubmed/31900204
http://dx.doi.org/10.1186/s13063-019-3846-x
Descripción
Sumario:ABSTRACT: The MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-β1b) investigates the efficacy of a combination therapy of lopinavir/ritonavir and recombinant interferon-β1b provided with standard supportive care, compared to placebo provided with standard supportive care, in hospitalized patients with laboratory-confirmed MERS. The MIRACLE trial is designed as a recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind randomized controlled trial. The aim of this article is to describe the statistical analysis plan for the MIRACLE trial. The primary outcome is 90-day mortality. The primary analysis will follow the intention-to-treat principle. The MIRACLE trial is the first randomized controlled trial for MERS treatment. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02845843. Registered on 27 July 2016.

Ejemplares similares